We're excited to invite you to our in-person event at the UCL Queen Square Institute of Neurology in London on the 13th of December, led by Queen Square Centre for Neuromuscular Diseases and UK DRI Biomarker Factory. Learn from our speakers how protein biomarkers are used to advance the search for new treatments for neurodegenerative disorders, can help detect disease before the onset of symptoms and monitor treatment response.
Register to secure your seat; we’re looking forward to meeting you during our four sessions for a morning of biomarkers in Neuroscience!
Date: Tuesday 13th December
Time: 10:00 - 12:00 GMT, with lunch following the event
Location: Inst Neurology - Queen Square (33) Basement Lecture Theatre (33LT) in Inst Neurology - Queen Square
Professor of Neurology
‘United to End MND and the use of Olink for biomarkers discovery in the translational pipeline, from cell lines to patients samples’
Prof. Henrik Zetterberg
Dr. Amanda Heslegrave
'A brief introduction to the Biomarker Factory'
Anne-Li Lind, PhD
Olink Proteomics
'How can Olink be used to address research questions in neurological diseases?'
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.